Bristol-Myers Squibb (BMS) and Daiichi Sankyo have entered a collaborative clinical trial to evaluate the combination of BMS’ immunotherapy Opdivo (nivolumab) and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers. “We are excited to evaluate if the combination of these two mechanisms of action—the ability of an anti-PD-1 to harness the immune system and the potential of DS-8201 to deliver chemotherapy directl...